{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:21:06Z","timestamp":1791105666114,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1016\/j.neuropharm.2004.03.011","type":"journal-article","created":{"date-parts":[[2004,6,11]],"date-time":"2004-06-11T16:44:35Z","timestamp":1086972275000},"page":"184-194","source":"Crossref","is-referenced-by-count":79,"title":["NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats"],"prefix":"10.1016","volume":"47","author":[{"given":"R.H.","family":"Wessell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.S.","family":"Menniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.L.","family":"Dunbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.N.","family":"Chase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2004.03.011_BIB1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0092-8674(02)00657-8","article-title":"Expression of constitutively active CREB protein facilitates the late phase of long-term potentiation by enhancing synaptic capture","volume":"108","author":"Barco","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB4","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/mds.870130507","article-title":"Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys","volume":"13","author":"Blanchet","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB5","first-page":"1034","article-title":"Differing effects of N-methyl-d-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys","volume":"290","author":"Blanchet","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0306-4522(99)00294-8","article-title":"Changes in the regional and compartmental distribution of FodB-and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic l-dopa treatment","volume":"94","author":"Cenci","year":"1999","journal-title":"Neurosci."},{"issue":"6","key":"10.1016\/j.neuropharm.2004.03.011_BIB9","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1046\/j.0953-816x.2001.01485.x","article-title":"Dopaminergic control of synaptic plasticity in the dorsal striatum","volume":"13","author":"Centonze","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB11","first-page":"S122","article-title":"Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications","volume":"47","author":"Chase","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB12","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1471-1931(00)00018-5","article-title":"Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism","volume":"23","author":"Chase","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF03033378","article-title":"Striatal glutamatergic mechanisms and extrapyramidal movement disorders","volume":"5","author":"Chase","year":"2003","journal-title":"Neurotoxicol. Res."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB17","first-page":"370","article-title":"CP-101606 Pfizer Inc","volume":"1","author":"Chazot","year":"2000","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0006-8993(96)01098-0","article-title":"Cellular distribution of the NMDA receptor NR2A\/2B subunits in the rat striatum","volume":"743","author":"Chen","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB21","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1046\/j.1432-1327.1999.00441.x","article-title":"Tyrosine phosphorylation modulates the interaction of calmodulin with its target proteins","volume":"262","author":"Corti","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB22","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/mds.1112","article-title":"Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study","volume":"16","author":"Del Dotto","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB24","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1523\/JNEUROSCI.21-15-05546.2001","article-title":"Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane","volume":"21","author":"Dunah","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB25","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1097\/00001756-199412000-00045","article-title":"NMDA receptor blockade reverses motor response alterations induced by levodopa","volume":"5","author":"Engber","year":"1994","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/hipo.1034","article-title":"PKC activation rescues LTP from NMDA receptor blockade","volume":"11","author":"Kleschevnikov","year":"2001","journal-title":"Hippocampus"},{"issue":"8","key":"10.1016\/j.neuropharm.2004.03.011_BIB28","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.54.8.1589","article-title":"AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys","volume":"54","author":"Konitsiotis","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0092-8674(03)00122-3","article-title":"Phosphorylation of the AMPA receptor GluR1 subunit is required for synaptic plasticity and retention of spatial memory","volume":"112","author":"Lee","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB32","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0006-8993(00)03163-2","article-title":"Potassium chloride depolarization mediates CREB phosphorylation in striatal neurons in an NMDA receptor-dependent manner","volume":"890","author":"Mac\u00edas","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/(SICI)1098-2396(20000615)36:4<267::AID-SYN3>3.0.CO;2-Y","article-title":"Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in parkinsonian rats","volume":"36","author":"Marin","year":"2000","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0167-4838(02)00315-1","article-title":"Sequence determinants on the NR2A and NR2B subunits of NMDA receptor responsible for specificity of phosphorylation by CaMKII","volume":"1598","author":"Mayadevi","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB37","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1527-3458.1998.tb00073.x","article-title":"CP-101,606: an NR2B selective NMDA receptor antagonist","volume":"4","author":"Menniti","year":"1998","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB38","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0028-3908(99)00211-7","article-title":"CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents","volume":"39","author":"Menniti","year":"2000","journal-title":"Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB40","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/mds.870130307","article-title":"A trial of dextromethrophan in Parkinsonian patients with motor response complications","volume":"13","author":"Metman","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB41","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.56.11.1383","article-title":"Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study","volume":"56","author":"Metman","year":"1999","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB43","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00002826-199712000-00004","article-title":"Motor complications of chronic levodopa therapy in Parkinson\u2019s disease","volume":"20","author":"Miyawaki","year":"1999","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB44","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/0028-3908(95)00109-J","article-title":"Structure and function of the NMDA receptor channel","volume":"34","author":"Mori","year":"1995","journal-title":"Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ana.410270105","article-title":"Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson\u2019s disease","volume":"27","author":"Mouradian","year":"1990","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB46","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/mds.10107","article-title":"Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat","volume":"17","author":"Nash","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB47","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1006\/exnr.2000.7444","article-title":"Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson\u2019s disease","volume":"165","author":"Nash","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB48","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00726-001-0118-2","article-title":"Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson\u2019s disease","volume":"23","author":"Oh","year":"2002","journal-title":"Amino Acids"},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB49","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(97)00355-8","article-title":"Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat","volume":"228","author":"Oh","year":"1997","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0006-8993(98)01049-X","article-title":"Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and l-DOPA administration","volume":"813","author":"Oh","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB51","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0006-8993(99)01121-X","article-title":"Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits","volume":"821","author":"Oh","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB52","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1006\/exnr.2002.8009","article-title":"Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models","volume":"177","author":"Oh","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB53","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/jnr.10629","article-title":"Cyclic AMP responsive element binding protein phosphorylation and persistent expression of levodopa-induced response alterations in unilateral nigrostriatal 6-OHDA lesioned rats","volume":"72","author":"Oh","year":"2003","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB54","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0006-8993(03)02348-5","article-title":"Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats","volume":"971","author":"Oh","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0006-8993(94)90796-X","article-title":"Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration","volume":"662","author":"Papa","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0006-8993(95)00924-3","article-title":"Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade","volume":"701","author":"Papa","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB58","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0896-6273(02)00684-0","article-title":"Reversible inhibition of CREB\/ATF transcription factors in region CA1 of the dorsal hippocampus disrupts hippocampus-dependent spatial memory","volume":"34","author":"Pittenger","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB59","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1212\/WNL.51.2_Suppl_2.S25","article-title":"Classification of fluctuations in patients with Parkinson\u2019s disease","volume":"51","author":"Quinn","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB60","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1523\/JNEUROSCI.17-13-05129.1997","article-title":"NMDA receptor and the tyrosine phosphorylation of its 2B subunit in taste learning in the rat insular cortex","volume":"17","author":"Rosenblum","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0014-4886(79)90003-7","article-title":"Excessive bracing reactions and their control by atropine and l-dopa in an animal analog of Parkinsonism","volume":"64","author":"Schallert","year":"1979","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB63","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1155\/NP.1992.332","article-title":"A clinically relevant unilateral rat model of Parkinsonian akinesia","volume":"3","author":"Schallert","year":"1992","journal-title":"J. Neural. Transplant. Plast."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB65","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1006\/nlme.2001.4022","article-title":"The role of PKA, CaMKII, and PKC in avoidance conditioning: permissive or instructive?","volume":"77","author":"Shobe","year":"2002","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB66","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1074\/jbc.R000013200","article-title":"Cellular signaling through multifunctional Ca2+\/calmodulin-dependent protein kinase II","volume":"276","author":"Soderling","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cne.903430102","article-title":"Organization of N-methyl-d-aspartate glutamate receptor gene expression in the basal ganglia of the rat","volume":"343","author":"Standaert","year":"1994","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB68","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1006\/exnr.2000.7374","article-title":"Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors","volume":"163","author":"Steece-Collier","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB72","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0014-2999(68)90164-7","article-title":"6-Hydorxydopamine induced degeneration of central monoamine neurons","volume":"5","author":"Ungerstedt","year":"1968","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2004.03.011_BIB74","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1074\/jbc.M006727200","article-title":"Calmodulin kinase II attenuation of gene transcription by preventing cAMP response element-binding protein (CREB) dimerization and binding of the CREB-binding protein","volume":"276","author":"Wu","year":"2001","journal-title":"J. Biol. Chem."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390804000851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390804000851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T05:22:22Z","timestamp":1549516942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390804000851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S0028390804000851"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2004.03.011","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}